Developer docs
API playgroundTry for free, no card

Search company profiles

Heartflow

Full company profile

uuid00000k8

Namestring
Heartflow
Legal namestring
Heartflow, Inc.
Websiteurl
heartflow.com
Company typeenum
Public
Founded yearint
2010
Descriptiontext

Heartflow is a medical technology company that develops an AI-powered platform for the non-invasive diagnosis and management of coronary artery disease (CAD). Its flagship product, Heartflow One, integrates four analytical modules — Roadmap Analysis (stenosis quantification), FFRCT Analysis (computational fluid dynamics-based fractional flow reserve), Plaque Analysis (plaque volume and characterization), and PCI Navigator (pre-procedural interventional planning) — into a single cloud-based workflow that processes standard coronary CT angiography (CCTA) scans into personalized 3D heart models. The underlying technology combines deep learning with proprietary computational fluid dynamics algorithms trained on approximately 273,000 patient records and validated against 110 million images.

Heartflow sells to hospitals, health systems, cardiology practices, and radiology departments through direct enterprise field sales and strategic partnerships, with platform adoption at 1,800+ institutions globally and 650,000+ patients managed to date. Revenue is generated primarily through insurance reimbursement rather than direct customer billing, with FFRCT Analysis covered under Category I CPT code 75580 (99.5% of US lives) and Plaque Analysis reimbursed under codes 75577 and 0623T-0626T (approximately 75% of US covered lives following UnitedHealthcare, Cigna, and Aetna coverage decisions). FY2025 revenue was $176 million, growing 40% year-over-year, with Q1 2026 revenue of $52.6 million (41% YoY growth) and full-year 2026 guidance of $218-222 million.

The company completed its NASDAQ IPO in August 2025 under ticker HTFL, raising $316.7 million. It operates as a remote-first organization with offices in San Francisco (headquarters), Austin, Rohnert Park, Mountain View, London, and Tokyo, and holds FDA 510(k) clearances, ISO 13485, ISO 27001, SOC 1, and HITRUST certifications. Competitive moats are anchored by 600+ global patents, Category I CPT reimbursement, ACC/AHA scientific statement endorsements, and an accumulating evidence base across 625+ peer-reviewed publications.

Short descriptiontext

Heartflow is a publicly traded medical technology company that provides an AI-powered platform for non-invasive diagnosis and management of coronary artery disease, serving 1,800+ hospitals, health systems, and cardiology practices across the US, UK, and Japan with cloud-based CCTA analysis reimbursed by major insurers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac diagnostic imaging, coronary CTA analysis, AI medical imaging, heart disease diagnostics, non-invasive cardiology
Industry2 codes
PRIMARYHLAKABAE
Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear)
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cardiac Diagnostic Imaging Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1FFRCT Analysis Reimbursement
TypeTransaction Fee
Description

Heartflow generates revenue through reimbursement codes for its FFRCT Analysis, covered by Category I CPT code 75580 with 99.5% of US lives covered by Medicare and commercial insurers

heartflow.com
2Plaque Analysis Reimbursement
TypeTransaction Fee
Description

Revenue from plaque analysis services billed under CPT codes (75577/0623T-0626T), with coverage from Medicare, UnitedHealthcare, Cigna, Aetna, and Humana representing approximately 75% of US covered lives

heartflow.com
3Roadmap Analysis
TypeSubscription Recurring
Description

Analysis provided with every CCTA sent to Heartflow, integrated into the platform subscription model

heartflow.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details2 tiers
1Hospital Outpatient (OPPS) pricing for CY 2026
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CCTA (APC 5572): $356; FFRCT (APC 5724): $877; Plaque Analysis (APC 1511): $950

heartflow.com
2Physician Office (PFS) pricing for CY 2026
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CCTA (75574): $326 professional fee $111; FFRCT (75580): $887 professional fee $34; Plaque (75577): $1021 professional fee $41

heartflow.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1Heartflow One
Description

Integrated AI platform for managing coronary artery disease throughout the care continuum, including Roadmap Analysis, FFRCT Analysis, Plaque Analysis, and support services

heartflow.com
+4 more records
Core offering1 text field

Heartflow provides AI-powered analysis of coronary CT angiography (CCTA) scans through its Heartflow One platform, converting standard cardiac CT images into personalized 3D models of the heart. The platform delivers four integrated diagnostic tools: FFRCT Analysis for non-invasive blood flow assessment, Plaque Analysis for quantifying and characterizing coronary plaque, Roadmap Analysis for AI-enabled stenosis quantification, and PCI Navigator for pre-procedural interventional planning.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 88% lower cardiovascular death rate at 3 years for patients with normal FFRCT
+7 more records
Product overview1 text field

Heartflow offers a unified platform called Heartflow One that provides AI-powered analysis for coronary artery disease management. The platform integrates four core products: FFRCT Analysis (for assessing blood flow and lesion-specific physiology), Plaque Analysis (for quantifying and characterizing coronary plaque), Roadmap Analysis (for efficient CCTA reading with consistent results), and PCI Navigator (for pre-procedural interventional planning). Together, these tools transform standard coronary CTA scans into personalized 3D models that help clinicians detect disease earlier, determine optimal treatment pathways, and manage patients for life.

Product and service6 records
1Heartflow One
CategoryCardiac Diagnostic Imaging Platform
Description

Unified AI-powered platform that transforms coronary CTA scans into personalized 3D heart models, integrating Roadmap Analysis, FFRCT Analysis, Plaque Analysis, and support services for comprehensive CAD management across the care continuum. Targeted at hospitals, health systems, and cardiology practices.

2FFRCT Analysis
CategoryCardiac Diagnostic Imaging Analysis
Description

Non-invasive diagnostic tool using computational fluid dynamics and deep learning to assess blood flow anywhere in the coronary tree and determine the benefit of revascularization, achieving 0.94 AUC for non-invasive CAD diagnosis. Sold to hospitals, cardiology practices, and radiology departments and reimbursed under Category I CPT code 75580.

3Plaque Analysis
CategoryCardiac Diagnostic Imaging Analysis
Description

AI-driven assessment that quantifies total plaque volume by type, determines plaque composition including high-risk non-calcified plaque, and delivers personalized preventive care recommendations with 95% agreement to invasive gold-standard IVUS. Sold to hospitals and cardiology practices and reimbursed under CPT codes 75577 and 0623T-0626T.

4Roadmap Analysis
CategoryCardiac Diagnostic Imaging Analysis
Description

AI-enabled coronary stenosis quantification tool that efficiently reads every CCTA with consistent results across readers, boosting reading efficiency by up to 25% and improving agreement between CT readers by over 40%. Sold to hospitals, cardiology practices, and radiology departments.

5PCI Navigator
CategoryCardiac Procedure Planning Software
Description

AI-driven tool for pre-procedural planning of percutaneous coronary interventions (PCI), providing interventional cardiologists with detailed 3D models of coronary anatomy, plaque, and lesion physiology for improved procedural planning. Sold to hospitals and interventional cardiology practices.

6Heartflow Support
CategoryCustomer Success and Implementation Services
Description

Comprehensive support services including CCTA education, coding and reimbursement support, technology integration assistance, educational resources, peer-to-peer education, and case support to help institutions build and scale CCTA programs. Sold as a service wrap around the Heartflow One platform.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-21
Description

The Christ Hospital Health Network announced participation as one of 17 sites nationwide (and the only site in Ohio) in Heartflow's GAMEFILM Registry, a study focused on advancing understanding of heart disease in former professional athletes using Heartflow Plaque Analysis and coronary computed tomography angiography.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

CVAUSA, a network of over 460 cardiovascular physicians operating at 100+ clinic locations in 8 states serving 1.3 million patients annually, announced implementation of Heartflow's AI-powered diagnostic technology across its clinical network. The Heartflow One platform provides non-invasive coronary artery disease detection through personalized 3D modeling and plaque analysis using CCTA imaging.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-11
Description

ADHS partnered with Heartflow to bring non-invasive coronary imaging technology to patients at River Oaks Hospital & Clinics and Advanced Dallas Hospital & Clinics in Texas. The collaboration aims to improve early cardiovascular disease detection and provide clearer diagnostic information to patients and physicians using AI-driven 3D modeling of coronary blood flow.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-11
Description

Banner Health formed a strategic partnership with HeartFlow to enhance cardiac diagnostics and procedures at its hospitals. The collaboration leverages HeartFlow's AI technology and PCI Navigator to improve patient assessment and interventional planning for coronary artery disease.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cleerly is a direct competitor providing AI-powered coronary CTA analysis for plaque characterization and stenosis assessment, recently endorsed alongside Heartflow by Aetna. The two companies are currently in active patent litigation, underscoring their direct product overlap in non-invasive CAD diagnostics.

TypeBroad incumbent
Description

GE HealthCare is a large incumbent in cardiac CT imaging hardware and post-processing software (Advantage Workstation, HeartStation). It competes with Heartflow by offering integrated cardiac CT analysis tools to the same hospital and cardiology customers, though as part of a much broader imaging portfolio.

TypeBroad incumbent
Description

Philips offers cardiac CT post-processing, advanced visualization, and AI-enabled analysis tools through its IntelliSpace Portal. It serves the same cardiology and radiology departments as Heartflow and competes for clinical workflow share, though its offerings sit inside a broader imaging and patient monitoring portfolio.

TypeBroad incumbent
Description

Siemens Healthineers provides cardiac CT scanners and the syngo.via post-processing platform with AI-driven cardiac analysis. It competes for the same hospital imaging budgets as Heartflow, with cardiac CT analysis as one component of a much larger diagnostic imaging portfolio.

TypeDirect peer
Description

Circle CVI provides advanced cardiac MR, CT, and echocardiography post-processing software used by the same cardiology and radiology departments as Heartflow. It is a direct peer in cardiac imaging workflow software with comparable clinical decision-support positioning.

TypeEmerging player
Description

Elucid develops AI software for non-invasive characterization of coronary plaque from CCTA, directly addressing the same plaque analysis workflow as Heartflow's Plaque Analysis product. It is a smaller emerging competitor focused specifically on plaque histology-style assessment.

TypeEmerging player
Description

Aidoc is an AI platform for medical imaging that includes cardiac CT analysis capabilities and integrates with hospital PACS workflows. It competes for AI-imaging budget at the same health systems as Heartflow, though with a broader multi-organ imaging focus.

TypeEmerging player
Description

Viz.ai provides AI-driven clinical workflow and imaging analysis, with growing cardiology applications alongside its core neurology focus. It targets similar hospital AI budgets and integrates with PACS/EMR systems the same way Heartflow does.

TypeEmerging player
Description

Us2.ai provides AI-based automated analysis of echocardiograms for cardiac function and disease characterization. It is an adjacent cardiology AI peer addressing non-invasive cardiac imaging, but on ultrasound rather than CT, with partial overlap in cardiology workflow customers.

TypeEmerging player
Description

Eko Health combines AI-enabled digital stethoscopes and cardiac analytics for earlier detection of heart disease. It is an emerging cardiology AI peer targeting earlier-stage screening and monitoring, complementing rather than directly competing with Heartflow's CT-based diagnostic workflow.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Heartflow

Cardiac Diagnostic Imaging Softwareheartflow.com

Heartflow is a publicly traded medical technology company that provides an AI-powered platform for non-invasive diagnosis and management of coronary artery disease, serving 1,800+ hospitals, health systems, and cardiology practices across the US, UK, and Japan with cloud-based CCTA analysis reimbursed by major insurers.

What Heartflow does

Heartflow is a medical technology company that develops an AI-powered platform for the non-invasive diagnosis and management of coronary artery disease (CAD). Its flagship product, Heartflow One, integrates four analytical modules — Roadmap Analysis (stenosis quantification), FFRCT Analysis (computational fluid dynamics-based fractional flow reserve), Plaque Analysis (plaque volume and characterization), and PCI Navigator (pre-procedural interventional planning) — into a single cloud-based workflow that processes standard coronary CT angiography (CCTA) scans into personalized 3D heart models. The underlying technology combines deep learning with proprietary computational fluid dynamics algorithms trained on approximately 273,000 patient records and validated against 110 million images.

Heartflow sells to hospitals, health systems, cardiology practices, and radiology departments through direct enterprise field sales and strategic partnerships, with platform adoption at 1,800+ institutions globally and 650,000+ patients managed to date. Revenue is generated primarily through insurance reimbursement rather than direct customer billing, with FFRCT Analysis covered under Category I CPT code 75580 (99.5% of US lives) and Plaque Analysis reimbursed under codes 75577 and 0623T-0626T (approximately 75% of US covered lives following UnitedHealthcare, Cigna, and Aetna coverage decisions). FY2025 revenue was $176 million, growing 40% year-over-year, with Q1 2026 revenue of $52.6 million (41% YoY growth) and full-year 2026 guidance of $218-222 million.

The company completed its NASDAQ IPO in August 2025 under ticker HTFL, raising $316.7 million. It operates as a remote-first organization with offices in San Francisco (headquarters), Austin, Rohnert Park, Mountain View, London, and Tokyo, and holds FDA 510(k) clearances, ISO 13485, ISO 27001, SOC 1, and HITRUST certifications. Competitive moats are anchored by 600+ global patents, Category I CPT reimbursement, ACC/AHA scientific statement endorsements, and an accumulating evidence base across 625+ peer-reviewed publications.

Heartflow firmographics

Firmographics
Name
Heartflow
Legal name
Heartflow, Inc.
Website
https://heartflow.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Heartflow is a publicly traded medical technology company that provides an AI-powered platform for non-invasive diagnosis and management of coronary artery disease, serving 1,800+ hospitals, health systems, and cardiology practices across the US, UK, and Japan with cloud-based CCTA analysis reimbursed by major insurers.
Ownership category
akta.pro rank

Heartflow industry classification

Industry
Product category
Cardiac Diagnostic Imaging Software
NAICS
Computer Systems Design and Related Services (54151)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAKABAE
Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear)
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

  • Cardiac diagnostic imaging
  • Coronary CTA analysis
  • AI medical imaging
  • Heart disease diagnostics
  • Non-invasive cardiology

Where Heartflow is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Heartflow business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. FFRCT Analysis Reimbursement: Heartflow generates revenue through reimbursement codes for its FFRCT Analysis, covered by Category I CPT code 75580 with 99.5% of US lives covered by Medicare and commercial insurers
  2. Plaque Analysis Reimbursement: Revenue from plaque analysis services billed under CPT codes (75577/0623T-0626T), with coverage from Medicare, UnitedHealthcare, Cigna, Aetna, and Humana representing approximately 75% of US covered lives
  3. Roadmap Analysis: Analysis provided with every CCTA sent to Heartflow, integrated into the platform subscription model

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goHospital Outpatient (OPPS) pricing for CY 2026
Unit PricingPay-as-you-goPhysician Office (PFS) pricing for CY 2026

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Heartflow product offering

Product offering

Core offering

Heartflow provides AI-powered analysis of coronary CT angiography (CCTA) scans through its Heartflow One platform, converting standard cardiac CT images into personalized 3D models of the heart. The platform delivers four integrated diagnostic tools: FFRCT Analysis for non-invasive blood flow assessment, Plaque Analysis for quantifying and characterizing coronary plaque, Roadmap Analysis for AI-enabled stenosis quantification, and PCI Navigator for pre-procedural interventional planning.

Product overview

Heartflow offers a unified platform called Heartflow One that provides AI-powered analysis for coronary artery disease management. The platform integrates four core products: FFRCT Analysis (for assessing blood flow and lesion-specific physiology), Plaque Analysis (for quantifying and characterizing coronary plaque), Roadmap Analysis (for efficient CCTA reading with consistent results), and PCI Navigator (for pre-procedural interventional planning). Together, these tools transform standard coronary CTA scans into personalized 3D models that help clinicians detect disease earlier, determine optimal treatment pathways, and manage patients for life.

Differentiator

Problem solved

Functional benefit

Brands

  • Heartflow One: Integrated AI platform for managing coronary artery disease throughout the care continuum, including Roadmap Analysis, FFRCT Analysis, Plaque Analysis, and support services
  • FFRCT Analysis
  • Roadmap Analysis
  • Plaque Analysis
  • PCI Navigator

Products and services

  • Heartflow One Unified AI-powered platform that transforms coronary CTA scans into personalized 3D heart models, integrating Roadmap Analysis, FFRCT Analysis, Plaque Analysis, and support services for comprehensive CAD management across the care continuum. Targeted at hospitals, health systems, and cardiology practices.
  • FFRCT Analysis Non-invasive diagnostic tool using computational fluid dynamics and deep learning to assess blood flow anywhere in the coronary tree and determine the benefit of revascularization, achieving 0.94 AUC for non-invasive CAD diagnosis. Sold to hospitals, cardiology practices, and radiology departments and reimbursed under Category I CPT code 75580.
  • Plaque Analysis AI-driven assessment that quantifies total plaque volume by type, determines plaque composition including high-risk non-calcified plaque, and delivers personalized preventive care recommendations with 95% agreement to invasive gold-standard IVUS. Sold to hospitals and cardiology practices and reimbursed under CPT codes 75577 and 0623T-0626T.
  • Roadmap Analysis AI-enabled coronary stenosis quantification tool that efficiently reads every CCTA with consistent results across readers, boosting reading efficiency by up to 25% and improving agreement between CT readers by over 40%. Sold to hospitals, cardiology practices, and radiology departments.
  • PCI Navigator AI-driven tool for pre-procedural planning of percutaneous coronary interventions (PCI), providing interventional cardiologists with detailed 3D models of coronary anatomy, plaque, and lesion physiology for improved procedural planning. Sold to hospitals and interventional cardiology practices.
  • Heartflow Support Comprehensive support services including CCTA education, coding and reimbursement support, technology integration assistance, educational resources, peer-to-peer education, and case support to help institutions build and scale CCTA programs. Sold as a service wrap around the Heartflow One platform.

Quantifiable outcome

  • 88% lower cardiovascular death rate at 3 years for patients with normal FFRCT
  • +7 more outcomes

Companies that use Heartflow

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Heartflow technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature4 records

Heartflow partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • The Christ Hospital Health NetworkminorStrategic or Co-development Partner · 21 April 2026The Christ Hospital Health Network announced participation as one of 17 sites nationwide (and the only site in Ohio) in Heartflow's GAMEFILM Registry, a study focused on advancing understanding of heart disease in former professional athletes using Heartflow Plaque Analysis and coronary computed tomography angiography.
  • Cardiovascular Associates of America (CVAUSA)coreStrategic or Co-development Partner · 24 March 2026CVAUSA, a network of over 460 cardiovascular physicians operating at 100+ clinic locations in 8 states serving 1.3 million patients annually, announced implementation of Heartflow's AI-powered diagnostic technology across its clinical network. The Heartflow One platform provides non-invasive coronary artery disease detection through personalized 3D modeling and plaque analysis using CCTA imaging.
  • Advanced Diagnostics Healthcare System (ADHS)coreStrategic or Co-development Partner · 11 February 2026ADHS partnered with Heartflow to bring non-invasive coronary imaging technology to patients at River Oaks Hospital & Clinics and Advanced Dallas Hospital & Clinics in Texas. The collaboration aims to improve early cardiovascular disease detection and provide clearer diagnostic information to patients and physicians using AI-driven 3D modeling of coronary blood flow.
  • Banner HealthcoreStrategic or Co-development Partner · 11 February 2026Banner Health formed a strategic partnership with HeartFlow to enhance cardiac diagnostics and procedures at its hospitals. The collaboration leverages HeartFlow's AI technology and PCI Navigator to improve patient assessment and interventional planning for coronary artery disease.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Heartflow competitors and assessment

Company assessment

Direct peers

  • Cleerly: Cleerly is a direct competitor providing AI-powered coronary CTA analysis for plaque characterization and stenosis assessment, recently endorsed alongside Heartflow by Aetna. The two companies are currently in active patent litigation, underscoring their direct product overlap in non-invasive CAD diagnostics.
  • Circle Cardiovascular Imaging: Circle CVI provides advanced cardiac MR, CT, and echocardiography post-processing software used by the same cardiology and radiology departments as Heartflow. It is a direct peer in cardiac imaging workflow software with comparable clinical decision-support positioning.

Broad incumbents

  • GE HealthCare: GE HealthCare is a large incumbent in cardiac CT imaging hardware and post-processing software (Advantage Workstation, HeartStation). It competes with Heartflow by offering integrated cardiac CT analysis tools to the same hospital and cardiology customers, though as part of a much broader imaging portfolio.
  • Philips: Philips offers cardiac CT post-processing, advanced visualization, and AI-enabled analysis tools through its IntelliSpace Portal. It serves the same cardiology and radiology departments as Heartflow and competes for clinical workflow share, though its offerings sit inside a broader imaging and patient monitoring portfolio.
  • Siemens Healthineers: Siemens Healthineers provides cardiac CT scanners and the syngo.via post-processing platform with AI-driven cardiac analysis. It competes for the same hospital imaging budgets as Heartflow, with cardiac CT analysis as one component of a much larger diagnostic imaging portfolio.

Emerging players

  • Elucid Bioimaging: Elucid develops AI software for non-invasive characterization of coronary plaque from CCTA, directly addressing the same plaque analysis workflow as Heartflow's Plaque Analysis product. It is a smaller emerging competitor focused specifically on plaque histology-style assessment.
  • Aidoc: Aidoc is an AI platform for medical imaging that includes cardiac CT analysis capabilities and integrates with hospital PACS workflows. It competes for AI-imaging budget at the same health systems as Heartflow, though with a broader multi-organ imaging focus.
  • Viz.ai: Viz.ai provides AI-driven clinical workflow and imaging analysis, with growing cardiology applications alongside its core neurology focus. It targets similar hospital AI budgets and integrates with PACS/EMR systems the same way Heartflow does.
  • Us2.ai: Us2.ai provides AI-based automated analysis of echocardiograms for cardiac function and disease characterization. It is an adjacent cardiology AI peer addressing non-invasive cardiac imaging, but on ultrasound rather than CT, with partial overlap in cardiology workflow customers.
  • Eko Health: Eko Health combines AI-enabled digital stethoscopes and cardiac analytics for earlier detection of heart disease. It is an emerging cardiology AI peer targeting earlier-stage screening and monitoring, complementing rather than directly competing with Heartflow's CT-based diagnostic workflow.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Heartflow social profiles

Digital presence

Heartflow compliance and trust

Trust signal

Compliance4 records

Heartflow financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Heartflow leadership team

Management profile

Number of profiles

Profiles19 records

Heartflow funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Heartflow M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Heartflow

What does Heartflow do?

Heartflow provides AI-powered analysis of coronary CT angiography (CCTA) scans through its Heartflow One platform, converting standard cardiac CT images into personalized 3D models of the heart. The platform delivers four integrated diagnostic tools: FFRCT Analysis for non-invasive blood flow assessment, Plaque Analysis for quantifying and characterizing coronary plaque, Roadmap Analysis for AI-enabled stenosis quantification, and PCI Navigator for pre-procedural interventional planning.

Is Heartflow a public or private company?

Heartflow is a public company. It is classified as public and is currently operating.

When was Heartflow founded?

Heartflow was founded in 2010. It employs 501 to 1,000 people.

Where is Heartflow based?

Heartflow is headquartered in San Francisco, United States, in the North America region.

How does Heartflow make money?

Three revenue lines are on record. FFRCT Analysis Reimbursement is the primary driver. The others are plaque Analysis Reimbursement and roadmap Analysis.

Who are Heartflow's main competitors?

Direct peers on record are Cleerly and Circle Cardiovascular Imaging. Broad incumbents are GE HealthCare, Philips and Siemens Healthineers. Emerging players are Elucid Bioimaging, Aidoc, Viz.ai, Us2.ai and Eko Health.

Does Heartflow have an API?

No public API is recorded for Heartflow.

What industry is Heartflow in?

Heartflow's product category is Cardiac Diagnostic Imaging Software. Its primary akta.pro industry code is HLAKABAE, Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear), with a secondary code of HLALAGAB, Cardiology Telemedicine Platforms. Its NAICS code is 54151 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Law360Quinn Emanuel Should Be DQ'd From IP Row, Heartflow SaysHeartflow Inc. asked a Texas federal court to disqualify Quinn Emanuel Urquhart & Sullivan LLP from representing its rival in an intellectual property dispute. The company said it nearly retained the firm and shared confidential information during the process.Seeking AlphaHeartFlow: A Post Q3 AssessmentHeartFlow, Inc. shares rallied after its August IPO but fell sharply after Q3 results on Friday. The company reports 50% sales growth but remains unprofitable, with a market cap of $4.12B and 47.43% revenue growth. Analysts maintain strong support for the stock.TradingViewFreedom Capital Markets maintains HeartFlow at Buy, raises price target to $59 from $44Freedom Capital Markets maintained HeartFlow at Buy and raised its price target to $59 from $44, a 34.1% increase. The target implies a 25.9% upside from the Nov 16 close of $46.86. Recent analyst price targets range from $64 to $70.YahooHeartFlow: 3 Key Takeaways for Long-Term InvestorsHeartFlow raised its full-year revenue outlook to $262–264 million in its Q3 2026 earnings call. Q3 revenue grew 57% to $72.9 million, with U.S. revenue up 60%. The company is initiating clinical trials in late 2026 to target an $11 billion market.The Motley FoolHeartFlow: 3 Key Takeaways for Long-Term InvestorsHeartFlow raised its full-year revenue outlook to $262–264 million in its Q3 2026 earnings call. Revenue grew 57% year-over-year to $72.9 million, with non-GAAP gross margin at 83.8%. The company is initiating clinical trials in late 2026 to target an $11 billion addressable market.TradingViewWells Fargo maintains HeartFlow at Overweight, raises price target to $70 from $39Wells Fargo maintained HeartFlow at Overweight and raised its price target to $70 from $39, a 79.5% increase. The target implies 16.8% upside from the Nov 12 close of $59.92. Recent analyst price targets range from $64 to $70.TradingViewHeartflow, Inc. Stock 12‑Month Price Target Raised to $62.5, Implies 4% UpsideAnalysts' average price target for Heartflow, Inc. rose to $62.5 from $50.5, implying about 4% upside from the Nov. 12 close. The consensus remains a Buy across nine analysts, with 8 Buys, 1 Hold, and no Sells.TradingViewStifel maintains HeartFlow at Buy, raises price target to $70 from $45Stifel maintained HeartFlow at Buy and raised its price target to $70 from $45, a 55.6% increase. The target implies an upside of 16.8% from the Nov 12 close of $59.92.TradingViewBaird maintains HeartFlow at Outperform, raises price target to $68 from $56Baird maintained HeartFlow at Outperform and raised its price target to $68 from $56, a 21.4% increase. The target implies a 13.5% upside from the Nov 12 close of $59.92.TradingViewHeartflow, Inc. Stock 12‑Month Price Target Raised to $59.12, Implies 1% DownsideAnalysts' average price target for Heartflow, Inc. rose to $59.12 from $50.5, implying about 1% downside from the Nov. 12 close. The consensus remains Buy across 9 analysts, with 8 Buys, 1 Hold, and 0 Sells.